Pangea

Pangea Biomed operates in the precision oncology sector, leveraging advanced RNA sequencing technology to identify and observe gene group interactions. The company's proprietary platform, ENLIGHT, predicts responses for dozens of cancer types and over a hundred oncology drugs, aiming to improve treatment outcomes for cancer patients. Pangea Biomed primarily serves oncologists and cancer treatment centers, providing them with data-driven insights to tailor treatments to individual patients. The company operates in the global healthcare market, focusing on oncology. Its business model involves offering subscription-based access to its platform and charging fees for detailed genomic analysis and treatment recommendations. Revenue is generated through these subscriptions and service fees. Pangea Biomed's mission is to bring effective precision oncology to cancer patients, enhance oncology drug development, and empower oncologists with actionable data.

Keywords: precision oncology, RNA sequencing, gene interactions, cancer treatment, ENLIGHT platform, oncology drugs, genomic analysis, healthcare, data-driven insights, personalized medicine.